JP2022552254A5 - - Google Patents

Info

Publication number
JP2022552254A5
JP2022552254A5 JP2022521217A JP2022521217A JP2022552254A5 JP 2022552254 A5 JP2022552254 A5 JP 2022552254A5 JP 2022521217 A JP2022521217 A JP 2022521217A JP 2022521217 A JP2022521217 A JP 2022521217A JP 2022552254 A5 JP2022552254 A5 JP 2022552254A5
Authority
JP
Japan
Prior art keywords
disease
nucleic acid
acid construct
construct according
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022521217A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022552254A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/055251 external-priority patent/WO2021072372A1/en
Publication of JP2022552254A publication Critical patent/JP2022552254A/ja
Publication of JP2022552254A5 publication Critical patent/JP2022552254A5/ja
Priority to JP2025167212A priority Critical patent/JP2026021331A/ja
Pending legal-status Critical Current

Links

JP2022521217A 2019-10-10 2020-10-12 バリアントigf2構築体 Pending JP2022552254A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025167212A JP2026021331A (ja) 2019-10-10 2025-10-03 バリアントigf2構築体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962913677P 2019-10-10 2019-10-10
US62/913,677 2019-10-10
US201962929054P 2019-10-31 2019-10-31
US62/929,054 2019-10-31
PCT/US2020/055251 WO2021072372A1 (en) 2019-10-10 2020-10-12 Variant igf2 constructs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025167212A Division JP2026021331A (ja) 2019-10-10 2025-10-03 バリアントigf2構築体

Publications (2)

Publication Number Publication Date
JP2022552254A JP2022552254A (ja) 2022-12-15
JP2022552254A5 true JP2022552254A5 (cg-RX-API-DMAC7.html) 2023-10-20

Family

ID=75438187

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022521217A Pending JP2022552254A (ja) 2019-10-10 2020-10-12 バリアントigf2構築体
JP2025167212A Pending JP2026021331A (ja) 2019-10-10 2025-10-03 バリアントigf2構築体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025167212A Pending JP2026021331A (ja) 2019-10-10 2025-10-03 バリアントigf2構築体

Country Status (12)

Country Link
US (1) US20240091321A1 (cg-RX-API-DMAC7.html)
EP (1) EP4041284A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022552254A (cg-RX-API-DMAC7.html)
KR (1) KR20220077921A (cg-RX-API-DMAC7.html)
CN (1) CN115087458A (cg-RX-API-DMAC7.html)
AU (2) AU2020361703A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022006842A2 (cg-RX-API-DMAC7.html)
CA (1) CA3154189A1 (cg-RX-API-DMAC7.html)
IL (1) IL292065A (cg-RX-API-DMAC7.html)
MX (1) MX2022004345A (cg-RX-API-DMAC7.html)
TW (1) TW202128740A (cg-RX-API-DMAC7.html)
WO (1) WO2021072372A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202344691A (zh) * 2018-04-30 2023-11-16 美商阿米庫斯醫療股份有限公司 基因治療構築體及使用方法
EP4081241A4 (en) 2019-12-24 2024-05-01 Juvena Therapeutics, Inc. REGENERATIVE POLYPEPTIDES AND USES THEREOF
WO2022119890A1 (en) 2020-12-01 2022-06-09 The Trustees Of The University Of Pennsylvania Compositions and uses thereof for treatment of angelman syndrome
EP4359425B1 (en) 2021-06-21 2026-08-05 Juvena Therapeutics, Inc. Igf2 fusion polypeptide and use in the treatment of muscular dystrophy, sarcopenia, cachexia, or muscle injury
EP4359430A4 (en) 2021-06-23 2025-07-16 Lycia Therapeutics Inc BIFUNCTIONAL COMPOUNDS CONTAINING IGF-2 POLYPEPTIDES
AU2023303015A1 (en) * 2022-07-06 2025-01-23 Research Institute At Nationwide Children's Hospital Adeno-associated virus delivery of cln1 polynucleotide
US20260216373A1 (en) * 2023-01-13 2026-07-30 Amicus Therapeutics, Inc. Gene Therapy Constructs for the Treatment of Pompe Disease
AU2024241509A1 (en) * 2023-03-20 2025-09-25 Spark Therapeutics, Inc. Ppt1 gene therapy
US20240360431A1 (en) * 2023-04-30 2024-10-31 Sichuan Real&Best Biotech Co., Ltd. Engineered alpha-galactosidase a (a-gal a) peptides and functional variants thereof and associated methods of treating fabry disease
PL445164A1 (pl) * 2023-06-07 2024-12-09 Recepton Spółka Z Ograniczoną Odpowiedzialnością Cząsteczki indukujące internalizację receptorów i białek zewnątrzkomórkowych
CN120025420A (zh) * 2023-11-21 2025-05-23 深圳湾实验室 用于蛋白降解的构建体及其应用
WO2025259950A1 (en) * 2024-06-14 2025-12-18 Cz Biohub Sf, Llc Genetically encoded lysosome targeting chimeras for cell-mediated delivery

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1436316B1 (en) * 2001-04-30 2008-01-23 ZyStor Therapeutics , Inc. Subcellular targeting of therapeutic proteins
US7560424B2 (en) * 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
DE602005020745D1 (de) * 2004-02-10 2010-06-02 Zystor Therapeutics Inc Saure alpha-glukosidase und fragmente davon
AU2006203882B2 (en) * 2005-01-07 2011-05-12 Regeneron Pharmaceuticals, Inc. IGF-1 fusion polypeptides and therapeutic uses thereof
LT2714752T (lt) * 2011-05-27 2018-03-12 Amicus Therapeutics, Inc. Nukreipiančių peptidų kopuliavimo ant rekombinantinių lizosominių fermentų būdai, skirti lizosominio kaupimo ligų gydymo pagerinimui
WO2014082080A2 (en) * 2012-11-26 2014-05-30 Callidus Biopharma, Inc. Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases
ES2679374T3 (es) * 2012-11-27 2018-08-24 Biomarin Pharmaceutical Inc. Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas
EP2976092B1 (en) * 2013-03-15 2020-04-22 Amicus Therapeutics, Inc. Chemical crosslinkers
WO2016025523A1 (en) * 2014-08-11 2016-02-18 Shire Human Genetic Therapies, Inc. Lysosomal targeting and uses thereof
EP3374504B1 (en) * 2015-11-09 2025-03-19 CureVac SE Optimized nucleic acid molecules
WO2018035563A1 (en) * 2016-08-24 2018-03-01 Immunexpress Pty Ltd Systemic inflammatory and pathogen biomarkers and uses therefor
TW202344691A (zh) * 2018-04-30 2023-11-16 美商阿米庫斯醫療股份有限公司 基因治療構築體及使用方法
US20220193261A1 (en) * 2019-04-30 2022-06-23 The Trustees Of The University Of Pennsylvania Compositions useful for treatment of pompe disease

Similar Documents

Publication Publication Date Title
US20220127326A1 (en) Targeted Therapeutic Lysosomal Enzyme Fusion Proteins and Uses Thereof
JP2007523648A5 (cg-RX-API-DMAC7.html)
ES2613691T3 (es) Métodos y composiciones para el tratamiento de enfermedades por almacenamiento lisosomal
JP2021521851A5 (cg-RX-API-DMAC7.html)
JP2015524662A5 (cg-RX-API-DMAC7.html)
KR102946363B1 (ko) 치료학적 효소류의 결합체
Aronson Jr et al. Lysosomal degradation of Asn‐linked glycoproteins
US9932568B2 (en) Peptide linkers for polypeptide compositions and methods for using same
EP1981546B1 (en) Enzyme replacement therapy for treating lysosomal storage diseases
EP1587923B1 (en) Improved constructs for expressing lysosomal polypeptides
ES2629853T3 (es) Péptidos de dirección lisosómica y usos de los mismos
US20080241118A1 (en) Methods and Compositions for Targeting Proteins Across the Blood Brain Barrier
JP2011521627A5 (cg-RX-API-DMAC7.html)
IL275248B2 (en) A therapeutic enzyme fusion protein with a novel structure and its use
KR20110089193A (ko) 식물 배양에서 고-만노스 단백질의 생산
JP2022512689A5 (cg-RX-API-DMAC7.html)
JP6594833B2 (ja) ポリペプチド組成物用ペプチドリンカーおよびその使用方法
EP1480510B1 (en) Expression of lysosomal enzymes in plant seeds
JP7791517B2 (ja) ライソゾームを標的とした新規ddsの開発
US20060188975A1 (en) Genetically modified somatic cells for sustained secretion of lysosomal proenzymes deficient in lysosomal storage disorders
Sakuraba et al. Molecular pathologies of and enzyme replacement therapies for lysosomal diseases
Anson et al. Sulphamidase
US20200206323A1 (en) An agent, a device and a blood-circulation system for treating lysosomal storage diseases, and a method for treating lysosomal storage diseases
RU2023123291A (ru) Антитела против рецептора трансферрина и их применение
Marković-Housley et al. MECHANISM OF BEE VENOM HYALURONIDASE, A MAJOR